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Abstract
Papillary thyroid cancer (PTC) is the second most commonly diagnosed malignancy in 
U.S. Latinas and in Colombian women. Studies in non-Latinos indicate that BRAF and TERT 
mutations are PTC prognostic markers. This study aimed to determine the prevalence and 
clinical associations of BRAF and TERT mutations in PTC Latino patients from Colombia. 
We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA 
from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, 
FVPTC) recruited through a multi-center study. Associations between mutations and clinical 
variables were evaluated with Fisher exact tests. Survival was evaluated with Kaplan–Meier 
plots. Double-mutant tumors (BRAF+/TERT+, n = 14 patients) were more common in CVPTC 
(P = 0.02). Relative to patients without mutations (n = 48), double mutations were more 
common in patients with large tumors (P = 0.03), lymph node metastasis (P = 0.01), extra-
thyroid extension (P = 0.03), and advanced stage (P = 6.0 × 10−5). In older patients, TERT 
mutations were more frequent (mean age 51 years vs 45 years for wild type TERT, P = 0.04) 
and survival was lower (HR = 1.20; P = 0.017); however, given the small sample size, the 
decrease in survival was not statically significant between genotypes. Comparisons with 
published data in US whites revealed that Colombian patients had a higher prevalence of 
severe pathological features and of double-mutant tumors (10 vs 6%, P = 0.001). Mutations 
in both oncogenes show prognostic associations in Latinos from Colombia. Our study is 
important to advance Latino PTC precision medicine and replicates previous prognostic 
associations between BRAF and TERT in this population.
Introduction
In the United States and several other countries, 
the incidence of papillary thyroid cancer (PTC) has 
significantly increased in recent decades (1). PTC is now 
the second most commonly diagnosed malignancy among 
US Latinas (2, 3). In Colombia, the country with the 
second largest Latino population in Latin America (4, 5), 
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incidence has also been increasing and PTC is now 
the third most common female cancer with an 
age-standardized rate of 14.5 per 100,000 people (4, 5, 6). 
We have previously shown that Colombian PTC patients 
have a higher prevalence of indicators of severity and 
aggressive tumor behavior, such as large size, extra-thyroid 
extension, and lymph node and distant metastasis, than 
reported in developed countries (7). In contrast to over-
diagnosis driven increases in incidence, which is common 
in developed countries, a smaller fraction of incidental 
diagnoses occurs in Colombia. This represents a unique 
opportunity to investigate the role of molecular makers in 
PTC etiology and prognosis.
Given the significant worldwide increase in PTC 
incidence (8), there is a great need to identify prognosis 
biomarkers that allow for effective patient stratification 
and management. The BRAF V600E mutation has been 
associated with tumorigenesis in a wide range of human 
malignancies (9) and represents the most common 
PTC mutation. BRAF V600E has been associated with 
clinicopathological features, such as lymph node 
metastasis and advanced disease stage (1, 10, 11), although 
the evidence is not consistent (12, 13, 14). Hence, BRAF 
V600E on its own has limited utility as a prognosis PTC 
biomarker. More recently, two TERT promoter mutations, 
C228T and C250T, were found in ~10% of PTC patients 
(15, 16, 17, 18, 19, 20) and have been associated with 
a higher risk of developing the classical variant of PTC 
(CVPTC) (15) and with disease severity (15, 18, 19, 20, 21, 
22, 23, 24, 25).
Given the high prevalence of BRAF and TERT 
mutations in PTC and their prognostic associations, there 
have been several studies showing the coexistence and 
cooperative role of these mutations in aggressive disease 
(15, 16, 17, 18, 19, 21, 23, 24, 26, 27), likely because the 
acquisition of a TERT mutation could extend the lifespan 
of BRAF- or RAS-driven clones and enable accumulation 
of additional genetic defects leading to more advanced 
disease. Double mutants (i.e., carrying both TERT promoter 
and BRAF mutations) are associated with older age at 
diagnosis, CVPTC (18, 19), large tumors (18, 22), extra-
thyroid extension (18, 22), lymph node (18) and distant 
metastasis (18, 19), advanced (18, 19, 22, 26), recurrence 
(18), and mortality (18, 23). Given the importance of 
BRAF and TERT mutations in PTC and the fact that these 
changes have not been examined in patients of Latino 
ancestry, we investigated the role of these mutations 
in clinical manifestations and the survival of patients 
recruited in a multi-center study in Colombia.
Materials and methods
Study population
The research protocol used in the study adhered to 
the Declaration of Helsinki and was approved by the 
Ethics Committees from University of Tolima (Ibague), 
Hospital Federico Lleras Acosta (Ibague), Clínica Tolima 
(Ibague), Hospital Hernando Moncaleano (Neiva), 
and Hospital Pablo Tobón Uribe (Medellin). These 
institutions are among the largest cancer hospitals in 
their corresponding cities. A total of 149 incident and 
histologically verified PTC patients, 81 with classical 
variant PTC (CVPTC) and 68 with follicular variant PTC 
(FVPTC), were recruited in between 2006 and 2016. 
All patients provided written informed consent, were 
interviewed in person by trained research nurses, and 
authorized access to pathology reports, clinical records, 
and to retrieve archival tumor samples for molecular 
analyses. We collected information on age of onset, 
gender, tumor size, focality, laterality, capsular or 
vascular invasion, lymph node metastases, extra-thyroid 
extension, distant metastasis, stage (AJCC), vital status, 
and cause of death.
Mutation status
A pathologist (MEB) demarcated tumor regions with 
>80% tumor cells on hematoxylin and eosin (H&E)- 
stained slides. We isolated the DNA from the demarcated 
regions using Qiagen DNeasy Blood & Tissue Kit and 
protocol. BRAF exon 15 and the TERT promoter region 
were amplified using previously reported primers (21, 
28) and Sanger sequenced. The PCR amplification 
failed in three samples for BRAF and eight for TERT 
(including those three samples that failed for BRAF) 
and were excluded from all subsequent analyses. 
The mutation status in BRAF (V600E) and TERT  
promoter (C228T, C250T) was inspected in 
electropherograms with 4 Peaks v. 1.7 (Nucleobytes 
B.V. 2004–2015) by two experienced independent 
researchers (APE and GPE). Mutation calling 
concordance was 100%.
Statistical analyses
Statistical analysis was performed with R (https://
www.r-project.org/). We stratified clinicopathological 
variables by histology (CVPTC and FVPTC) and 
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compared the histological subtypes using chi-square 
(for dichotomous variables) and Student’s t tests (for 
continuous variables, for which we verified that they 
were normally distributed). The association between 
mutation status and various characteristics, such as 
gender, age at diagnosis, histopathological subtype, 
tumor size, lymph node metastasis, and tumor stage, 
were determined by calculation of odds ratios; statistical 
significance was considered when two-sided P values 
were <0.05. Comparisons of mutation prevalence 
were carried out using a Student’s t test and data from 
the Cancer Genome Atlas (TCGA) (29) and the Johns 
Hopkins Hospital PTC cohort (23). Survival curves, 
stratified by mutational status, were calculated with 
the Kaplan–Meier method and compared with log-
rank test using survival v2.41-3 (https://cran.r-project.
org/package=survival). Vital status (alive or death) was 
determined by investigating databases affiliated to the 
Colombian health system (Base de Datos Unica de 
Afiliados del Sistema General de Seguridad Social en 
Salud) and the National Civil Registry (Registraduria 
Nacional del Estado Civil) dataset. The last vital status 
assessment in all patients was carried out in December 
2017, which resulted in a mean follow-up time of 74.5 
months/patient (standard deviation (s.d.): 29.8).
Results
Characteristics of the study population
The characteristics of Colombian patients are shown 
in Table 1. In total, 80% (113 of 141) of these patients 
were women. The mean age of diagnosis was 45.9 years 
(s.d. = 13.7), large tumors (>2 cm) were diagnosed in 40% 
of the patients, 38% had multifocal disease, 20% had 
bilateral tumors, 30% had capsular invasion, 38% had 
vascular invasion, 36% had lymph node metastases, 26% 
had extra-thyroid extension, 6% had distant metastasis, 
and 30% of patients were classified with stage III/IV. At the 
final follow up, 94% of patients were alive. No statistical 
differences were found in tumor features between the two 
histopathological subtypes (Table 1).
Comparisons of clinical data in Colombian (Latino) 
patients with that in non-Latinos from TCGA and 
from the Johns Hopkins Hospital cohort are shown in 
Supplementary Table 1 (see section on supplementary 
data given at the end of this article). Relative to TCGA, 
we found a higher prevalence of FVPTC (47 vs 15%, 
P = 1.74 × 10−9) in Colombia. Comparisons with the 
Johns Hopkins Hospital cohort (23) revealed that 
Colombians had a higher prevalence of FVPTC (47 
vs 25%, P = 2.4 × 10−8), large tumors (mean tumor size 
Table 1 Clinical and histological characteristics of the 141 Colombian PTC patients analyzed in the study, stratified by histologic 
subtype.
Clinical feature
Number of patients (%)
P valueAll (n = 141) CVPTC (n = 75) FVPTC (n = 66)
Male gender 28 (19.9) 18 10 0.189
Mean age in years 45.9 45.1 46.7 0.506
 <45 years 57 (40.4) 33 24
 ≥45 years 84 (59.6) 42 42 0.357
Mean tumor size 2.35 2.37 2.32 0.858
Large tumors, >2 cm 54 (40.3) 26 28 0.436
Multifocal tumors 51 (37.5) 24 27 0.352
Bilateral tumors 25 (19.7) 14 11 0.653
Capsular invasion 38 (30.2) 24 14 0.052
Vascular invasion 47 (38.2) 24 23 0.978
 LNM 46 (36.2) 29 17 0.080
 ETT 34 (26.2) 19 15 0.555
Distant metastasis 8 (5.7) 6 2 0.203
Stage III–IVa 42 (30.4) 25 17 0.302
Vital statusb
 Alive 129 (94.2) 66 63
 Dead 8 (5.8) 5 3 0.719
Cancer-related death 4 (2.9) 3 1 0.620
Mean follow-up in months 74.5 73.5 75.6 0.669
aBased on American Joint Committee on Cancer (AJCC) protocol of classification but including two patients diagnosed before 45 years with metastasis. 
bVital status was unknown in four patients.
CVPTC, classical variant of PTC (papillary thyroid carcinoma); FVPTC, follicular variant of PTC; LNM, lymph node metastasis; ETT, extra-thyroid extension.
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2.35 cm vs 1.5 cm, P = 5.8 × 10−51), vascular invasion (38 vs 
15%, P = 1.5 × 10−10), extra-thyroid extension (26 vs 18%, 
P = 0.016), and advanced stage (30 vs 20%, P = 0.004). 
These comparisons with US patients suggest that PTC 
diagnoses in Colombia are belated, resulting in a higher 
prevalence of advanced tumors.
Individual effects of BRAF and TERT mutations
The prevalence of BRAF V600E mutations in our study 
was 60% (49 of 75 CVPTCs, and 35 of 66 FVPTCs had 
V600E), which was lower than in TCGA data (70%, 
P = 0.058, Supplementary Table 1) but higher than in 
the Johns Hopkins Hospital cohort (34%, P = 2.0 × 10−5, 
Supplementary Table 1). We found that BRAF V600E was 
more frequent in patients with lymph node metastases 
(34 of 84 vs 12 of 57; P = 0.04, Supplementary Table 2). 
As reported in other populations, CVPTC patients with 
advanced stage tumors had a higher prevalence of BRAF 
mutation (21 of 25 vs 28 of 48 of early stage CVPTCs; 
P = 0.03 not shown) (1, 10, 11).
The presence of high-risk clinicopathological 
characteristics did not show sex differences although 
most of aggressive features had a higher frequency in men 
(Supplementary Table 3). This was also observed when 
patients were stratified by BRAF mutation status, where 
men had a higher risk of prevalence of BRAF wild type 
tumors with lymph node metastasis (5 of 12 men and 7 
of 45 women who were BRAF wild type had lymph node 
metastases, P = 0.03). The latter finding is consistent with 
previous reports suggesting that male sex is a risk factor 
for aggressive disease (30, 31).
The two mutations in the TERT promoter were 
mutually exclusive in our study and were identified in 
16% of the patients (14 patients had tumors with the 
TERT C228T mutation and nine with TERT C250T). This 
TERT mutation prevalence in Colombia was two-fold 
higher than in TCGA (8%, P = 0.017; Supplementary Table 
1) (23, 29). Consistent with previous reports (21), we 
found that TERT mutations were associated with a late age 
of diagnosis (mean age at diagnosis 51.3 years for TERT 
mutant tumors vs 44.8 years for TERT wild type tumors, 
P = 0.04). TERT mutations were also more frequent in 
patients with extra-thyroid extension (9 of 23 vs 25 of 
118, P = 0.007), and with advanced stage tumors (13 of 25 
vs 29 of 118, P = 0.001) (Supplementary Table 2). These 
associations between TERT mutation status and aggressive 
clinical manifestations are consistent with previous 
reports in other populations (15, 18, 22, 23, 24).
The combined effects of BRAF V600E and TERT 
promoter mutations
We found that 10% (n = 14) of our patients had mutations 
in both BRAF and TERT (herein referred to as double-
mutants), a prevalence that is higher than in the Johns 
Hopkins Hospital cohort (6%, P = 0.001, Supplementary 
Table 1). The comparisons between the clinicopathological 
characteristics of double-mutants with those in wild type 
patients for both genes (double-wild types, n = 48 patients) 
are shown in Table 2. Comparisons between all four 
mutation subgroups are shown in Supplementary Table 
4. Compared to double-wild types, double-mutants were 
diagnosed at older age (56 years vs 45 years, P = 0.003) and 
had a higher prevalence of CVPTC (11 of 14 vs 21 of 48, 
P = 0.022), large tumors (8 of 14 vs 16 of 48, P = 0.026), 
lymph node metastasis (7 of 14 vs 9 of 48, P = 0.009), 
extra-thyroid extension (6 of 14 vs 11 of 48, P = 0.028), 
and tumors with advanced stage (11 of 14 vs 10 of 48, 
P = 6.0 × 10−5). Therefore, our study in Latinos replicates 
previously reported associations of double mutants in 
white/Caucasian patients with CVPTC (18, 19), age of 
diagnosis (18, 19, 22), tumor size (18, 22), extra-thyroid 
extension (18, 22), lymph node metastasis (18), and 
advanced disease stage (18, 19, 22, 26).
Exploratory analyses of survival
In our study, the overall mortality (i.e., by any cause) was 
6% (8 of 137 patients in available vital status; Table 1). 
Of the eight deceased patients, four died of cancer and 
four of unknown reasons. Cancer-specific mortality was 
associated with older age at diagnosis (HR = 1.20; P = 0.017) 
and patients with TERT promoter mutations generally had 
a lower chance of survival (HR = 3.9; P = 0.17 and Fig. 1). 
This association with mortality in our study replicates the 
prognostic value of TERT mutations in an independent 
population (21, 22, 24, 25). Given the relatively small 
sample size of our study, we were unable to determine the 
statistical support of potential prognostic factors, such 
as BRAF mutations, TERT mutations, older age, advance 
stage, and CVPTC histology, to survival. Future studies 
should include a larger sample size to further investigate 
factors related to survival.
Discussion
The increment of PTC incidence in developed countries 
might be explained by the over-diagnosis of small 
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incidental tumors (32). However, few studies have also 
noted that the prevalence of large (33, 34) and aggressive 
tumors is also increasing (33, 35), suggesting that factors 
other than overdiagnosis might be affecting the increase 
of PTC incidence (36). Relative to reports in white patients 
from the U.S. (23), we found a higher prevalence of 
aggressive disease. A total of 30% of Colombian patients 
had stage III/IV tumors, 40% had large tumors >2 cm, and 
6% had metastases to lungs and medulla, which support 
the notion of belated diagnosis rather than of incidental 
over-diagnosis. Therefore, the absence of confounding 
factors resulting from over-diagnosis indicates that factors 
influencing incidence and disease aggressiveness can be 
better studied in populations like Colombia.
Thyroid cancer is now the third most diagnosed 
cancer in Colombian women (6) and the second in US 
Latinas. A recent report from the American Cancer Society 
found that 9% of the newly diagnosed cancer patients in 
US Latinas (2, 6) and 5% in US white women are now 
PTC patients (6). The high incidence of PTC in Latinas 
is puzzling and could be explained, in part, by high rates 
of obesity in both US Latinas (where overweight/obesity 
rates are ~two-fold higher than in white women) (37) 
and Colombians (where obesity rates increased by 18% 
between 2005 and 2010) (38, 39, 40). Other population-
specific factors, such as American Indian ancestry, 
which influences cancer patters in the region (41, 42, 43) 
or other unidentified etiological factors may mediate the 
risk of PTC in the population.
Even though recent studies suggest that CVPTCs 
tend to have more aggressive clinical manifestations 
Table 2 Comparison of clinical characteristics between wild-type tumors versus those with both BRAF V600E and TERT promoter 
mutations (double mutants).
Clinical feature
Number of patients (%)
OR (95% CI) P valueaNo mutation (n = 48) Double mutants (n = 14)
Male gender 10 4 1.52 (0.39–5.88) 0.542
Mean age (s.d.) 44.7 (14.6) 55.5 (9.33) NA 0.003
 <45 years 20 3
 ≥45 years 28 11 2.62 (0.65–10.62) 0.168
CVPTC subtype 21 11 4.71 (1.16–19.08) 0.022
Large tumors (>2 cm) 16 8 4.83 (1.12–20.82) 0.026
Multifocal tumors 17 4 0.97 (0.25–3.82) 0.971
Bilateral tumors 5 2 1.56 (0.26–9.37) 0.628
Capsular invasion 12 5 3.33 (0.76–14.54) 0.098
Vascular invasion 16 5 2.92 (0.61–13.85) 0.166
 LNM 9 7 6.03 (1.43–25.32) 0.009
 ETT 11 6 4.64 (1.10–19.50) 0.028
Distant metastasis 3 2 2.50 (0.37–16.70) 0.331
Stage III-IVb 10 11 19.80 (3.76–104.3) 6.0 × 10−5
Vital status
 Alive 43 13 Reference
 Dead 4 1 0.83 (0.08–8.06) 0.870
Cancer-related death 1 1 3.31 (0.19–56.64) 0.428
aStatistically significant two-tailed P values are shown in bold. bBased on American Joint Committee on Cancer (AJCC) protocol of classification but 
including two patients diagnosed before 45 years with metastasis.
CVPTC, classical variant of PTC (papillary thyroid carcinoma); ETT, extra-thyroid extension; FVPTC, follicular variant of PTC; LNM: lymph node metastasis; 
s.d., standard deviation.
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Figure 1
Effects of TERT promoter mutations on cancer-survival of PTC patients 
(log-rank test = 2.16, df = 1, P = 0.14).
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and worse outcomes (44), our study failed to detect 
statistically significant differences between the CVPTC 
and FVPTC subtypes (Table 1). However, we found a 
trend where CVPTCs, relative to FVPTCs, had a higher 
frequency of high-risk features, such as vascular invasion 
(32 vs 21%, P = 0.052, Table 1) or lymph node metastasis 
(39 vs 23%, P = 0.08, Table 1), which is consistent with 
a previous report in 1293 patients (44). Consistent with 
this observation, we found that most double mutants 
(11 out 14, Table 2) were CVPTCs, which may indicate 
that this histological subtype could be more aggressive 
than FVPTCs. We acknowledge that out failure to detect 
differences in clinical manifestations between the two 
histological subtypes is likely the result of limited power 
given our small sample size.
We found TERT mutations in 16% of the patients and 
these mutations were associated with a two-fold increment 
of the risk of extra-thyroid extension and of advanced 
stage. When BRAF and TERT promoter mutations were 
analyzed together, double-mutants compared to double-
wild types had a six-fold higher risk of lymph node 
metastasis and a 20-fold higher risk of advanced tumors. 
The coexistence of TERT and BRAF mutations was also 
significantly associated with older age (Table 2). These 
clinical features have been associated with mortality in 
several studies (16, 22, 24, 25, 26, 45), demonstrating that 
TERT mutations, rather than BRAF-V600E, were restricted 
to PTC patients >45 years. This highlights the specific role 
of the age of patients in the mutational event (21). Hence, 
our study provides further support for the prognostic 
importance of TERT mutations in PTC.
PTC survival is mainly affected by tumor stage, with 
patients with stage IV tumors having the lowest survival 
rates (46). Survival up to 10 years in our sample was 89%, 
which is similar to the survival rate found by a recent 
report from the Colombian National Cancer Institute 
(47) but lower than reports from US patients (i.e., ~95%) 
(48). This observation further suggests that relative to 
US white patients, Colombians are more likely to have 
severe PTC. Future studies involving US Latinos and other 
US minorities are therefore warranted to assess whether 
survival and clinical manifestations are more severe, 
relative to white patients.
In the Johns Hopkins Hospital cohort, the analyses of 
the combined effects of BRAF-TERT mutations (i.e., double-
mutants) revealed a significant association with mortality, 
which remained strong after multivariate adjustment for 
all of the conventional clinicopathological characteristics, 
demonstrating the independent role of double-mutant 
stats in PTC-related mortality. Exploratory analyses in our 
cohort suggested that TERT promoter mutations and a late 
age of onset appear to be stronger predictors than BRAF 
mutations. We acknowledge that our sample size is small 
and hence, under-powered to draw stronger conclusions 
on the combined role of BRAF/TERT mutation status on 
PTC mortality. Additionally, the clinic-based setting of our 
study may not reflect the characteristics of the patients of 
the general population and may have introduced some 
biases. However, population-based studies in Colombia 
(and in most of Latin America) are unfeasible due to the 
lack of country-wide cancer registries. Here, we made an 
effort to recruit patients from the largest cancer hospitals 
in their corresponding cities. Nonetheless, we believe that 
the multi-site nature of the study is a close reflection of 
the characteristics of the general population.
In summary, we found a high fraction of Colombian 
patients with large and advanced tumors and with distant 
metastasis, suggesting that most patients were not the 
result of incidental findings. To our knowledge, this is 
the first study of BRAF and TERT promoter mutations in 
Colombia and in Latinos. We found strong associations 
between BRAF and TERT promoter mutations and PTC 
prognosis, suggesting that these mutations could be a 
factor explaining the aggressiveness of the disease in this 
study. We believe that this report represents an important 
initial step to develop precision medicine for PTC in 
Latinos from the Americas.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0376.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This study was supported by grants from COLCIENCIAS (Graduate 
Studentship from Programa de Doctorados Nacionales to APE-F, 
COLCIENCIAS – 647/2014), L’OREAL-UNESCO-ICETEX-COLCIENCIAS 
(Programa Mujeres para la Ciencia to APE-F – 3900917/2017), and 
Universidad del Tolima (Grants to MEB and ME, projects 400111, 360113, 
and 170130517). L G C-C acknowledges funding from the University of 
California Davis (start-up funds and Dean’s Fellowship in Precision Health 
Equity) and from the National Cancer Institute of the National Institutes of 
Health (P30CA093373 Cancer Center Support Grant). This content is solely 
the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0376
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
A P Estrada-Florez et al. BRAF/TERT mutations in Latino 
thyroid cancer
13168:9
Acknowledgments
The authors are grateful to all of the individuals who participated in the 
study and to the organizations that provided research funding.
References
 1 Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, 
Yip L, Mian C, Vianello F, Tuttle RM, et al. Association between 
BRAF V600E mutation and mortality in patients with papillary 
thyroid cancer. JAMA 2013 309 1493–1501. (https://doi.org/10.1001/
jama.2013.3190)
 2 Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, 
Tortolero-Luna G, Martinez-Tyson D, Jemal A & Siegel RL. Cancer 
statistics for Hispanics/Latinos, 2018. CA: A Cancer Journal for 
Clinicians 2018 68 425–445. (https://doi.org/10.3322/caac.21494)
 3 Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, 
Martinez-Tyson D & Jemal A. Cancer statistics for Hispanics/Latinos, 
2015. CA: A Cancer Journal for Clinicians 2015 65 457–480. (https://
doi.org/10.3322/caac.21314)
 4 Carvajal-Carmona LG, Ophoff R, Service S, Hartiala J, Molina J, 
Leon P, Ospina J, Bedoya G, Freimer N & Ruiz-Linares A. Genetic 
demography of Antioquia (Colombia) and the Central Valley 
of Costa Rica. Human Genetics 2003 112 534–541. (https://doi.
org/10.1007/s00439-002-0899-8)
 5 Criollo-Rayo AA, Bohorquez M, Prieto R, Howarth K, Culma C, 
Carracedo A, Tomlinson I, Echeverry de Polnaco MM, Carvajal 
Carmona LG & CHIBCHA Consortium. Native American gene 
continuity to the modern admixed population from the Colombian 
Andes: implication for biomedical, population and forensic studies. 
Forensic Science International: Genetics 2018 36 e1–e7. (https://doi.
org/10.1016/j.fsigen.2018.06.006)
 6 International Agency for Research on Cancer. CANCER Today, Data 
Visualization Tools for Exploring the Global Cancer Burden in 2018. Lyon, 
France: IARC, 2018. (available at: https://gco.iarc.fr/today/home)
 7 Estrada-Florez AP, Bohorquez ME, Sahasrabudhe R, Prieto R, Lott P, 
Duque CS, Donado J, Mateus G, Bolanos F, Velez A, et al. Clinical 
features of Hispanic thyroid cancer cases and the role of known 
genetic variants on disease risk. Medicine 2016 95 e4148. (https://doi.
org/10.1097/MD.0000000000004148)
 8 Wiltshire JJ, Drake TM, Uttley L & Balasubramanian SP. Systematic 
review of trends in the incidence rates of thyroid cancer. Thyroid 
2016 26 1541–1552. (https://doi.org/10.1089/thy.2016.0100)
 9 Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, 
Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the 
BRAF gene in human cancer. Nature 2002 417 949–954. (https://doi.
org/10.1038/nature00766)
 10 Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, 
Molinaro E, Agate L, Biagini A, Lupi C, et al. The BRAF(V600E) 
mutation is an independent, poor prognostic factor for the outcome 
of patients with low-risk intrathyroid papillary thyroid carcinoma: 
single-institution results from a large cohort study. Journal of Clinical 
Endocrinology and Metabolism 2012 97 4390–4398. (https://doi.
org/10.1210/jc.2012-1775)
 11 Fakhruddin N, Jabbour M, Novy M, Tamim H, Bahmad H, Farhat F, 
Zaatari G, Aridi T, Kriegshauser G, Oberkanins C, et al. BRAF and 
NRAS mutations in papillary thyroid carcinoma and concordance in 
BRAF mutations between primary and corresponding lymph node 
metastases. Scientific Reports 2017 7 4666. (https://doi.org/10.1038/
s41598-017-04948-3)
 12 Gandolfi G, Sancisi V, Piana S & Ciarrocchi A. Time to re-consider the 
meaning of BRAF V600E mutation in papillary thyroid carcinoma. 
International Journal of Cancer 2015 137 1001–1011. (https://doi.
org/10.1002/ijc.28976)
 13 Dong SY, Zeng RC, Jin LP, Yang F, Zhang XJ, Yao ZH, Zhang XH & 
Wang OC. BRAF(V600E) mutation is not associated with central 
lymph node metastasis in all patients with papillary thyroid cancer: 
different histological subtypes and preoperative lymph node status 
should be taken into account. Oncology Letters 2017 14 4122–4134.
 14 Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A & Orloff LA. 
Lack of association of BRAF mutation with negative prognostic 
indicators in papillary thyroid carcinoma: the University of 
California, San Francisco, experience. JAMA Otolaryngology: Head 
and Neck Surgery 2013 139 1164–1170. (https://doi.org/10.1001/
jamaoto.2013.4501)
 15 Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, 
Celestino R, Prazeres H, Lima L, et al. Frequency of TERT promoter 
mutations in human cancers. Nature Communications 2013 4 2185. 
(https://doi.org/10.1038/ncomms3185)
 16 Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, 
El-Naggar AK & Xing M. Highly prevalent TERT promoter mutations 
in aggressive thyroid cancers. Endocrine-Related Cancer 2013 20 
603–610. (https://doi.org/10.1530/ERC-13-0210)
 17 Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, 
Ghossein RA & Fagin JA. Frequent somatic TERT promoter mutations 
in thyroid cancer: higher prevalence in advanced forms of the 
disease. Journal of Clinical Endocrinology and Metabolism 2013 98 
E1562–E1566. (https://doi.org/10.1210/jc.2013-2383)
 18 Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & 
Bishop J. BRAF V600E and TERT promoter mutations cooperatively 
identify the most aggressive papillary thyroid cancer with highest 
recurrence. Journal of Clinical Oncology 2014 32 2718–2726. (https://
doi.org/10.1200/JCO.2014.55.5094)
 19 Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A & 
Sancisi V. TERT promoter mutations are associated with distant 
metastases in papillary thyroid carcinoma. European Journal of 
Endocrinology 2015 172 403–413. (https://doi.org/10.1530/EJE-14-
0837)
 20 Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S, 
Magnani E, Pignatti E, Vigo B, et al. Telomerase in differentiated 
thyroid cancer: promoter mutations, expression and localization. 
Molecular and Cellular Endocrinology 2015 399 288–295. (https://doi.
org/10.1016/j.mce.2014.10.019)
 21 Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C 
& Xu D. The age- and shorter telomere-dependent TERT promoter 
mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014 
33 4978–4984. (https://doi.org/10.1038/onc.2013.446)
 22 Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, 
Yu H, Wang Y, et al. TERT promoter mutations and their association 
with BRAF V600E mutation and aggressive clinicopathological 
characteristics of thyroid cancer. Journal of Clinical Endocrinology and 
Metabolism 2014 99 E1130–E1136. (https://doi.org/10.1210/jc.2013-
4048)
 23 Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW & Xing M. 
Mortality risk stratification by combining BRAF V600E and TERT 
promoter mutations in papillary thyroid cancer: genetic duet of 
BRAF and TERT promoter mutations in thyroid cancer mortality. 
JAMA Oncology 2017 3 202–208. (https://doi.org/10.1001/
jamaoncol.2016.3288)
 24 Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, 
Celestino R, Almeida A, Salgado C, Eloy C, et al. TERT promoter 
mutations are a major indicator of poor outcome in differentiated 
thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 
2014 99 E754–E765. (https://doi.org/10.1210/jc.2013-3734)
 25 Bullock M, Ren Y, O’Neill C, Gill A, Aniss A, Sywak M, Sidhu S, 
Delbridge L, Learoyd D, de Vathaire F, et al. TERT promoter 
mutations are a major indicator of recurrence and death due 
to papillary thyroid carcinomas. Clinical Endocrinology 2016 85 
283–290. (https://doi.org/10.1111/cen.12999)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0376
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
A P Estrada-Florez et al. BRAF/TERT mutations in Latino 
thyroid cancer
1317
PB–8
8:9
 26 Lee SE, Hwang TS, Choi YL, Han HS, Kim WS, Jang MH, Kim SK & 
Yang JH. Prognostic significance of TERT promoter mutations in 
papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent 
population. Thyroid 2016 26 901–910. (https://doi.org/10.1089/
thy.2015.0488)
 27 Insilla AC, Proietti A, Borrelli N, Macerola E, Niccoli C, Vitti P, 
Miccoli P & Basolo F. TERT promoter mutations and their correlation 
with BRAF and RAS mutations in a consecutive cohort of 145 thyroid 
cancer cases. Oncology Letters 2018 15 2763–2770. (https://doi.
org/10.3892/ol.2017.7675)
 28 Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA. High prevalence of 
BRAF gene mutation in papillary thyroid carcinomas and thyroid 
tumor cell lines. Cancer Research 2003 63 4561–4567.
 29 Cancer Genome Atlas Research Network. Integrated genomic 
characterization of papillary thyroid carcinoma. Cell 2014 159 
676–690. (https://doi.org/10.1016/j.cell.2014.09.050)
 30 Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA & 
Winchester DJ. Risk factors for central lymph node metastasis 
in papillary thyroid carcinoma: a National Cancer Data Base 
(NCDB) study. Surgery 2016 159 31–39. (https://doi.org/10.1016/j.
surg.2015.08.032)
 31 Wang F, Zhao S, Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, 
Fugazzola L, Colombo C, et al. BRAF V600E confers male sex 
disease-specific mortality risk in patients with papillary thyroid 
cancer. Journal of Clinical Oncology 2018 36 2787–2795. (https://doi.
org/10.1200/JCO.2018.78.5097)
 32 Jegerlehner S, Bulliard JL, Aujesky D, Rodondi N, Germann S, 
Konzelmann I, Chiolero A & NICER Working Group. Overdiagnosis 
and overtreatment of thyroid cancer: a population-based temporal 
trend study. PLoS ONE 2017 12 e0179387. (https://doi.org/10.1371/
journal.pone.0179387)
 33 Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE 
& Devesa SS. Rising thyroid cancer incidence in the United States 
by demographic and tumor characteristics, 1980–2005. Cancer 
Epidemiology, Biomarkers and Prevention 2009 18 784–791. (https://
doi.org/10.1158/1055-9965.EPI-08-0960)
 34 Pellegriti G, Frasca F, Regalbuto C, Squatrito S & Vigneri R. 
Worldwide increasing incidence of thyroid cancer: update on 
epidemiology and risk factors. Journal of Cancer Epidemiology 2013 
2013 965212. (https://doi.org/10.1155/2013/965212)
 35 Simard EP, Ward EM, Siegel R & Jemal A. Cancers with increasing 
incidence trends in the United States: 1999 through 2008. CA: 
A Cancer Journal for Clinicians 2012 62 118–128. (https://doi.
org/10.3322/caac.20141)
 36 McLeod DS, Sawka AM & Cooper DS. Controversies in primary 
treatment of low-risk papillary thyroid cancer. Lancet 2013 381 
1046–1057. (https://doi.org/10.1016/S0140-6736(12)62205-3)
 37 Hales C, Carroll M, Fryar C & Ogden C. Prevalence of obesity among 
adults and youth: United States, 2015–2016. In NCHS Data Brief, No. 
288, October 2017. Hyattsville, MD, USA: U.S. Department of HHS, 
CDC, NCHS, 2017. (available at: https://www.cdc.gov/nchs/data/
databriefs/db288.pdf)
 38 Forrest KYZ, Leeds MJ & Ufelle AC. Epidemiology of obesity in 
the Hispanic adult population in the United States. Family and 
Community Health 2017 40 291–297. (https://doi.org/10.1097/
FCH.0000000000000160)
 39 Harikrishna A, Ishak A, Ellinides A, Saad R, Christodoulou H, 
Spartalis E & Paschou SA. The impact of obesity and insulin 
resistance on thyroid cancer: a systematic review. Maturitas 2019 125 
45–49. (https://doi.org/10.1016/j.maturitas.2019.03.022)
 40 Kasper NM, Herran OF & Villamor E. Obesity prevalence in 
Colombian adults is increasing fastest in lower socio-economic 
status groups and urban residents: results from two nationally 
representative surveys. Public Health Nutrition 2014 17 2398–2406. 
(https://doi.org/10.1017/S1368980013003418)
 41 Hoffman J, Fejerman L, Hu D, Huntsman S, Li M, John EM, Torres-
Mejia G, Kushi L, Ding YC, Weitzel J, et al. Identification of novel 
common breast cancer risk variants at the 6q25 locus among Latinas. 
Breast Cancer Research 2019 21 3. (https://doi.org/10.1186/s13058-
018-1085-9)
 42 Sahasrabudhe R, Estrada A, Lott P, Martin L, Echeverry GP, Velez A, 
Neta G, Takahasi M, Saenko V, Mitsutake N, et al. The 8q24 
rs6983267G variant is associated with increased thyroid cancer risk. 
Endocrine-Related Cancer 2015 22 841–849. (https://doi.org/10.1530/
ERC-15-0081)
 43 Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman KB, 
Caswell JL, Tsung K, John EM, Torres-Mejia G, Carvajal-Carmona L, 
et al. Genome-wide association study of breast cancer in Latinas 
identifies novel protective variants on 6q25. Nature Communications 
2014 5 5260. (https://doi.org/10.1038/ncomms6260)
 44 Henke LE, Pfeifer JD, Baranski TJ, DeWees T & Grigsby PW. Long-
term outcomes of follicular variant vs classic papillary thyroid 
carcinoma. Endocrine Connections 2018 7 1226–1235. (https://doi.
org/10.1530/EC-18-0264)
 45 Nixon IJ, Wang LY, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG 
& Ganly I. The impact of nodal status on outcome in older patients 
with papillary thyroid cancer. Surgery 2014 156 137–146. (https://
doi.org/10.1016/j.surg.2014.03.027)
 46 Loh KC, Greenspan FS, Gee L, Miller TR & Yeo PP. Pathological 
tumor-node-metastasis (pTNM) staging for papillary and follicular 
thyroid carcinomas: a retrospective analysis of 700 patients. Journal 
of Clinical Endocrinology and Metabolism 1997 82 3553–3562. (https://
doi.org/10.1210/jcem.82.11.4373)
 47 Pardo C & de Vries E. Supervivencia global de pacientes con cáncer 
en el Instituto Nacional de Cancerología (Inc). Revista Colombiana 
de Cancerología 2017 21 12–18. (https://doi.org/10.1016/j.
rccan.2017.01.003)
 48 Sipos JA & Mazzaferri EL. Thyroid cancer epidemiology and 
prognostic variables. Clinical Oncology 2010 22 395–404. (https://doi.
org/10.1016/j.clon.2010.05.004)
Received in final form 8 August 2019
Accepted 22 August 2019
Accepted Preprint published online 27 August 2019
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0376
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
